Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Prospective Analysis of Loteprednol Etabonate Ophthalmic Suspension 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty
Sponsor: Kala Pharmaceuticals, Inc.
Listed as NCT05136443, this PHASE4 trial focuses on Corneal Edema and Corneal Endothelial Dystrophy and remains completed. Sponsored by Kala Pharmaceuticals, Inc., it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Feb 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Dec 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kala Pharmaceuticals, Inc.
- Price Vision Group
For direct contact, visit the study record on ClinicalTrials.gov .